Identification of differentially expressed genes in aflatoxin B1-treated cultured primary rat hepatocytes and Fischer 344 rats.
Aflatoxin B1 (AFB1), a mutagen and hepatocarcinogen in rats and humans, is a contaminant of the human food supply, particularly in parts of Africa and Asia. AFB1-induced changes in gene expression may play a part in the development of the toxic, immunosuppressive and carcinogenic properties of this fungal metabolite. An understanding of the-role of AFB1 in modulating gene regulation should provide insight regarding mechanisms of AFB1-induced carcinogenesis. We used three PCR-based subtractive techniques to identify AFB1-responsive genes in cultured primary rat hepatocyte RNA: differential display PCR (DD-PCR), representational difference analysis (RDA) and suppression subtractive hybridization (SSH). Each of the three techniques identified AFB1-responsive genes, although no individual cDNA was isolated by more than one technique. Nine cDNAs isolated using DD-PCR, RDA or SSH were found to represent eight genes that are differentially expressed as a result of AFB1 exposure. Genes whose mRNA levels were increased in cultured primary rat hepatocytes after AFB1 treatment were corticosteroid binding globulin (CBG), cytochrome P450 4F1 (CYP4F1), alpha-2 microglobulin, C4b-binding protein (C4BP), serum amyloid A-2 and glutathione S-transferase Yb2 (GST). Transferrin and a small CYP3A-like cDNA had reduced mRNA levels after AFB1 exposure. Full-length CYP3A mRNA levels were increased. When liver RNA from AFB1-treated male F344 rats was evaluated for transferrin, CBG, GST, CYP3A and CYP4F1 expression, a decrease in transferrin mRNA and an increase in CBG, GST, CYP3A and CYP4F1 mRNA levels was also seen. Analysis of the potential function of these genes in maintaining cellular homeostasis suggests that their differential expression could contribute to the toxicity associated with AFB1 exposure.
Harris
A J
AJ
Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA. ajharris@nctr.fda.gov
Shaddock
J G
JG
Manjanatha
M G
MG
Lisenbey
J A
JA
Casciano
D A
DA
D016604:Aflatoxin B1 / Q000633:toxicity*; D000818:Animals; D015152:Blotting, Northern; D002273:Carcinogens / Q000633:toxicity*; D003169:Complement Inactivator Proteins; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D005189:False Positive Reactions; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000235:genetics; D005982:Glutathione Transferase / Q000378:metabolism; D006023:Glycoproteins; D008297:Male; D009153:Mutagens / Q000633:toxicity*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D011951:Receptors, Complement / Q000378:metabolism; D014156:Transcortin / Q000378:metabolism; D014168:Transferrin / Q000378:metabolism
D002273:Carcinogens; D003169:Complement Inactivator Proteins; D006023:Glycoproteins; D009153:Mutagens; D012333:RNA, Messenger; D011951:Receptors, Complement; D014168:Transferrin; D014156:Transcortin; D003577:Cytochrome P-450 Enzyme System; D016604:Aflatoxin B1; D005982:Glutathione Transferase